TrialClinical drug investigation2018

A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease.

Rachel Gurrell et al.PubMed ↗Publisher ↗

No numbers read from the abstract.